Pathologic characterization of human prostate tissue with proton MR spectroscopy

Radiology

Volumn 228, Issue 1, 2003, Pages 144-151

  Swindle, Peter ^a   McCredie, Simon ^a   Russell, Peter ^a   Himmelreich, Uwe ^a   Khadra, Mohammed ^a   Lean, Cynthia ^a   Mountford, Carolyn ^a  

^a NONE

Author keywords

Magnetic resonance (MR), spectroscopy; Prostate neoplasms, MR; Prostate, biopsy; Prostate, MR

Indexed keywords

BIOCHEMICAL MARKER; CHOLINE; CREATINE; LIPID; LYSINE;

ACCURACY; ADULT; AGED; ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

EID: 0037700121     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2281011808     Document Type: Article

References (40)

1. van der Hoek R. Malignant neoplasms of the prostate: Disease Registers Unit. Australia: Australian Institute of Health and Welfare, 1995.
2. Hirst GH, Ward JE, Del Mar CB. Screening for prostate cancer: the case against. Med J Aust 1996; 164:285-288.
3. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50:7-33.
4. McNeal JE. Structure and pathology of the prostate. In: Goland M, ed. Normal and abnormal growth of the prostate. Springfield, III; Thomas, 1975; 750:55-65.
5. McNeal JE. Normal and pathologic anatomy of prostate. Urology 1981; 17:11-16.
6. McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988; 12:619-633.
7. Aihara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 1994; 43:60-67.
8. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111:58-64.
9. McNeal JE. Normal anatomy of the prostate and changes in benign prostatic hypertrophy and carcinoma. Semin Ultrasound CT MR 1988; 9:329-334.
10. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12:897-906.
11. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281:1395-1400.
12. Scardino PT. The Gordon Wilson lecture: natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc 2000; 111:201-241.
13. Delikatny EJ, Russell P, Hunter JC, et al. Proton MR and human cervical neoplasia: ex vivo spectroscopy allows distinction of invasive carcinoma of the cervix from carcinoma in situ and other preinvasive lesions. Radiology 1993; 188:791-796.
14. Rutter A, Hugenholtz H, Saunders JK, Smith IC. Classification of brain tumors by ex vivo 1H NMR spectroscopy. J Neurochem 1995; 64:1655-1661.
15. Lean CL, Delbridge L, Russell P, et al. Diagnosis of follicular thyroid lesions by proton magnetic resonance on fine needle biopsy. J Clin Endocrinol Metab 1995; 80:1306-1311.
16. Lean CL, Newland RC, Ende DA, Bokey EL, Smith IC, Mountford CE. Assessment of human colorectal biopsies by 1H MRS: correlation with histopathology. Magn Reson Med 1993; 30:525-533.
17. Mackinnon WB, Huschtscha L, Dent K, Hancock R, Paraskeva C, Mountford CE. Correlation of cellular differentiation in human colorectal carcinoma and adenoma cell lines with metabolite profiles determined by 1H magnetic resonance spectroscopy. Int J Cancer 1994; 59:248-261.
18. Wallace JC, Raaphorst GP, Somorjai RL, et al. Classification of 1H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminant analysis. Magn Reson Med 1997; 38:569-576.
19. Mackinnon WB, Barry PA, Malycha PL, et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 1997; 204:661-666.
20. Barry P, Wadstrom C, Falk G, et al. What is the value of 1H MRS in detecting early malignant changes? In: Giuli R, ed. The oesophagrogastric junction. Montrouge, France: John Libbey Eurotext, 1998; 1122-1127.
21. Soper R, Himmelreich U, Painter D, et al. Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance and statistical classification strategies. Pathology 2002; 34:417-422.
22. Lean CL, Somorjai RL, Smith ICP, Russell P, Mountford CE. Accurate diagnosis and prognosis of human cancers by proton MRS and a three stage classification strategy. In: Webb G, ed. Annual reports on NMR spectroscopy. London, England: Academic Press, 2002; 71-111.
23. Mountford CE, Somorjai RL, Malycha P, et al. Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine needle aspirates analyzed using a statistical classification strategy. Br J Surg 2001; 88:1234-1240.
24. Kurhanewicz J, Vigneron DB, Hricak H, et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 1996; 200:489-496.
25. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996; 198:795-805.
26. Yacoe ME, Sommer G, Peehl D. In vitro proton spectroscopy of normal and abnormal prostate. Magn Reson Med 1991; 19:429-438.
27. Cornel EB, Heerschap A, Smits GA, Oosterhof GO, Debruyne FM, Schalken JA, Magnetic resonance spectroscopy detects metabolic differences between seven Dunning rat prostate tumor sublines with different biological behavior. Prostate 1994; 25:19-28.
28. Kurhanewicz J, Dahiya R, Macdonald JM, Chang LH, James TL, Narayan P. Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med 1993; 29:149-157.
29. Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995; 45:459-466.
30. Lynch MJ, Nicholson JK. Proton MRS of human prostatic fluid: correlations between citrate, spermine, and myo-inositol levels and changes with disease. Prostate 1997; 30:248-255.
31. van der Graff M, Schipper RG. 1H MRS of prostatic tissue focussed on the detection of spermine, a possible biomarker of malignant behaviour in prostate cancer (abstr). In: Book of abstracts: Society of Magnetic Resonance in Medicine 1998. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1998; 613.
32. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999; 213:473-480.
33. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164:400-404.
34. Yu KK, Scheidler J, Hricak, H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999; 213:481-488.
35. Hahn P, Smith ICP, Leboldus L, Littman C, Somorjai RL, Bezabeh T. The classification of benign and malignant human prostate tissue by multivariate analysis of H-1 magnetic resonance spectra. Cancer Res 1997; 57:3398-3401.
36. Doran S, Falk G, Somorjai R, et al. Pathology of Barrett's esophagus by proton magnetic resonance spectroscopy and a statistical classification strategy. Am J Surg 2003; 185:232-238.
37. Polacarz S, Darne J, Sheridan E, Ginsberg R, Sharp F. Endocervical carcinoma and precursor lesions: c-myc expression and the demonstration of field changes. J Clin Pathol 1991; 44:896-899.
38. Delikatny EJ, Hull WE, Mountford CE. The effect of altering time domains and window functions in two-dimensional proton COSY spectra of biological specimens. J Magn Reson 1991; 94:463-473.
39. Swindle PW. Distinguishing adenocarcinoma of the prostate from benign prostatic hyperplasia using proton magnetic resonance spectroscopy. Thesis. University of Sydney, Australia, 2000.
40. Sabel MS, Zhang P, Barnwell JM, Winston JS, Hurd TC, Edge SB. Accuracy of sentinel node biopsy in predicting nodal status in patients with breast carcinoma. J Surg Oncol 2001; 77:243-246.